NCT05915351View on ClinicalTrials.gov

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Pancreatic Ductal AdenocarcinomaPancreas AdenocarcinomaPancreas Cancer
Interventions
DRUG

Enfortumab vedotin

Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days

Trial Locations (1)

66205

University of Kansas Cancer Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT05915351 - Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | Biotech Hunter | Biotech Hunter